Cargando…
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With (212)Pb-TCMC-Trastuzumab
PURPOSE: One-year monitoring of patients receiving intraperitoneal (IP) (212)Pb-TCMC-trastuzumab to provide long-term safety and outcome data. A secondary objective was to study 7 tumor markers for correlation with outcome. METHODS: Eighteen patients with relapsed intra-abdominal human epidermal gro...
Autores principales: | Meredith, Ruby F., Torgue, Julien J., Rozgaja, Tania A., Banaga, Eileen P., Bunch, Patty W., Alvarez, Ronald D., Straughn, J. Michael, Dobelbower, Michael C., Lowy, Andrew M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449266/ https://www.ncbi.nlm.nih.gov/pubmed/27906723 http://dx.doi.org/10.1097/COC.0000000000000353 |
Ejemplares similares
-
Toxicological Studies of (212)Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial
por: Milenic, Diane E., et al.
Publicado: (2015) -
Gene expression profiling upon (212)Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model
por: Yong, Kwon J, et al.
Publicado: (2013) -
(212)Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint
por: Yong, K J, et al.
Publicado: (2013) -
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate (212)Pb-NNV003
por: Maaland, Astri Fjelde, et al.
Publicado: (2020) -
Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial
por: Milenic, Diane E., et al.
Publicado: (2015)